ERIS - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 2.4
| Stock Code | ERIS | Market Cap | 18,808 Cr. | Current Price | 1,358 ₹ | High / Low | 1,910 ₹ |
| Stock P/E | 63.3 | Book Value | 203 ₹ | Dividend Yield | 0.54 % | ROCE | 6.86 % |
| ROE | 3.02 % | Face Value | 1.00 ₹ | DMA 50 | 1,371 ₹ | DMA 200 | 1,458 ₹ |
| Chg in FII Hold | -0.46 % | Chg in DII Hold | 0.04 % | PAT Qtr | 17.0 Cr. | PAT Prev Qtr | 150 Cr. |
| RSI | 49.8 | MACD | -2.44 | Volume | 24,064 | Avg Vol 1Wk | 65,484 |
| Low price | 1,200 ₹ | High price | 1,910 ₹ | PEG Ratio | -1.46 | Debt to equity | 0.79 |
| 52w Index | 22.2 % | Qtr Profit Var | 853 % | EPS | 20.8 ₹ | Industry PE | 30.9 |
📊 ERIS stock shows weak fundamentals for long-term investment. The valuation is stretched (P/E 63.3 vs industry 30.9), efficiency metrics are poor (ROE 3.02%, ROCE 6.86%), and the PEG ratio is negative (-1.46), indicating growth does not justify valuation. Dividend yield is modest at 0.54%, but profitability has dropped sharply (PAT from 150 Cr. to 17 Cr.). Technical indicators (MACD negative, price below DMA 200) suggest weakness. RSI at 49.8 shows neutral momentum.
💡 Entry Price Zone: Safer accumulation would be near 1,200–1,250 ₹, closer to the lower band of its 52-week range, only if fundamentals improve.
📈 Exit / Holding Strategy: If already holding, consider exiting on rallies toward 1,500–1,600 ₹. Long-term holding is only advisable if ROE, ROCE, and earnings stabilize. Otherwise, redeployment into stronger peers may be more rewarding.
✅ Positive
- Large market cap of 18,808 Cr. provides stability.
- EPS of 20.8 ₹ indicates earnings visibility.
- Pharma industry outlook remains strong.
⚠️ Limitation
- High valuation compared to industry peers.
- Weak return metrics (ROE, ROCE).
- Negative PEG ratio highlights poor growth vs valuation.
📉 Company Negative News
- Quarterly PAT dropped significantly (150 Cr. → 17 Cr.).
- FII holding decreased (-0.46%).
- Stock trading below DMA 200, showing weakness.
📈 Company Positive News
- DII holding increased slightly (+0.04%).
- Quarterly profit variation shows potential rebound (853%).
- Debt-to-equity ratio at 0.79 remains manageable.
🏭 Industry
- Pharma industry PE at 30.9 is much lower than ERIS, showing sector strength but company overvaluation.
- Healthcare demand and innovation continue to support industry growth.
🔎 Conclusion
ERIS is currently overvalued with weak efficiency and declining profitability. It is not a strong candidate for long-term investment unless fundamentals improve. Best strategy: wait for correction near 1,200–1,250 ₹ for entry, or exit on rallies if already holding.